Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate von Morcos, P. N., Moreira, S. A., Brennan, B. J., Blotner, S., Shulman, N. S., Smith, P. F.

Volltext

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C von Brennan, B. J., Morcos, P. N., Wang, K., Blotner, S. D., Morrison, R., Hagedorn, C. H., Marbury, T. C., Sulkowski, M., Grippo, J. F.

Volltext

Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC von Zhou, C., Lu, Y., Kim, S.-W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J.-J., Cheng, Y., Lee, S.H., Bu, L., Xu, T., Yang, L., Wang, C., Morcos, P.N., Mitry, E., Liu, T., Zhang, L.

Volltext

Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue von Stroh, M, Carlile, DJ, Li, C‐C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J‐E, Xhu, Z‐X, Morcos, PN, Davis, JD, Phipps, A

Volltext

Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell l... von Zhou, C., Lu, Y., Kim, S.-W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J.-J., Cheng, Y., Lee, S.H., Bu, L., Xu, T., Yang, L., Wang, C., Morcos, P.N., Mitry, E., Li, Z.

Volltext

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial von Hutchings, Martin, Morschhauser, Franck, Iacoboni, Gloria, Carlo-Stella, Carmelo, Offner, Fritz C., Sureda, Anna, Salles, Gilles, Martinez-Lopez, Joaquin, Crump, Michael, Thomas, Denise N., Morcos, Peter N., Ferlini, Cristiano, Broeske, Ann-Marie E., Belousov, Anton, Bacac, Marina, Dimier, Natalie, Carlile, David J., Lundberg, Linda, Perez-Callejo, David, Umana, Pablo, Moore, Tom, Weisser, Martin, Dickinson, Michael J.

Volltext

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study von Ou, Sai-Hong Ignatius, Ahn, Jin Seok, De Petris, Luigi, Govindan, Ramaswamy, Yang, James Chih-Hsin, Hughes, Brett, Lena, Hervé, Moro-Sibilot, Denis, Bearz, Alessandra, Ramirez, Santiago Viteri, Mekhail, Tarek, Spira, Alexander, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Monnet, Annabelle, Zeaiter, Ali, Kim, Dong-Wan

Volltext

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer von Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, De Petris, Luigi, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C., Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Zeaiter, Ali, Shaw, Alice T.

Volltext

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer von Ou, Sai-Hong Ignatius, Gadgeel, Shirish M., Barlesi, Fabrice, Yang, James Chih-Hsin, De Petris, Luigi, Kim, Dong-Wan, Govindan, Ramaswamy, Dingemans, Anne-Marie, Crino, Lucio, Léna, Hervé, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Mitry, Emmanuel, Müller, Barbara, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Shaw, Alice T.

Volltext

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC) von Barlesi, F., Dingemans, A.-M.C., Yang, J.C.-H., Ou, S.-H.I., Ahn, J.S., De Petris, L., Hughes, B., Lena, H., Bordogna, W., Golding, S., Morcos, P.N., Balas, B., Zeaiter, A., Kim, D.-W.

Volltext

LBA2Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-ce... von Zhou, C, Lu, Y, Kim, S-W, Reungwetwattana, T, Zhou, J, Zhang, Y, He, J, Yang, J-J, Cheng, Y, Lee, S H, Bu, L, Xu, T, Yang, L, Wang, C, Morcos, P N, Mitry, E, Li, Z

Volltext

LBA10Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC von Zhou, C, Lu, Y, Kim, S-W, Reungwetwattana, T, Zhou, J, Zhang, Y, He, J, Yang, J-J, Cheng, Y, Lee, S H, Bu, L, Xu, T, Yang, L, Wang, C, Morcos, P N, Mitry, E, Liu, T, Zhang, L

Volltext

CD20‐TCB (RG6026), A NOVEL “2:1” FORMAT T‐CELL‐ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA von Dickinson, M.J., Morschhauser, F., Iacoboni, G., Carlo‐Stella, C., Offner, F.C., Sureda, A., Salles, G., Martinez, J., Crump, M., Thomas, D.N., Morcos, P.N., Ferlini, C., Broeske, A., Bacac, M., Dimier, N.J., Umaña, P., Moore, T., Weisser, M., Hutchings, M.

Volltext

Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects von Morcos, Peter N., Guerini, Elena, Parrott, Neil, Dall, Georgina, Blotner, Steven, Bogman, Katrijn, Sturm, Carolina, Balas, Bogdana, Martin‐Facklam, Meret, Phipps, Alex

Volltext

Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib von Morcos, Peter N., Cleary, Yumi, Guerini, Elena, Dall, Georgina, Bogman, Katrijn, Petris, Luigi, Viteri, Santiago, Bordogna, Walter, Yu, Li, Martin‐Facklam, Meret, Phipps, Alex

Volltext

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC) von Ou, Sai-Hong Ignatius, Gandhi, Leena, Gadgeel, Shirish M., Barlesi, Fabrice, Yang, James Chih-Hsin, De Petris, Luigi, Kim, Dong-Wan, Govindan, Ramaswamy, Dingemans, Anne-Marie C., Crino, Lucio, Herve, Lena, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Zeaiter, Ali Hassan, Müller, Barbara, Johannsdottir, Hrefna, Balas, Bogdana, Morcos, Peter N., Shaw, Alice

Volltext

The pharmacokinetics of peginterferon alfa‐2a and ribavirin in A frican A merican, H ispanic and C aucasian patients with chronic hepatitis C von Brennan, B. J., Morcos, P. N., Wang, K., Blotner, S. D., Morrison, R., Hagedorn, C. H., Marbury, T. C., Sulkowski, M., Grippo, J. F.

Volltext

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer von Yang, JC-H, Ou, S-HI, De Petris, L, Gadgeel, S, Gandhi, L, Kim, D-W, Barlesi, F, Govindan, R, Dingemans, A-MC, Crino, L, Lena, H, Popat, S, Ahn, JS, Dansin, E, Golding, S, Bordogna, W, Balas, B, Morcos, PN, Zeaiter, A, Shaw, AT

Volltext

Rheumatoid Arthritis: Treatment [151-201]: 151. Should we be Looking More Carefully for Methotrexate Induced Liver Disease? von Lloyd, M., Makadsi, R., Ala, A., Connor, P., Gwynne, C., Rhys Dillon, B., Lawson, T., Emery, P., Mease, P. J., Rubbert-Roth, A., Curtis, J. R., Muller-Ladner, U., Gaylis, N., Armstrong, G. K., Reynard, M., Tyrrell, H., Joshi, N., Loke, Y., MacGregor, A., Malaiya, R., Rachapalli, S. M., Parton, T., King, L., Parker, G., Nesbitt, A., Schiff, M., Sheikzadeh, A., Formosa, D., Domanska, B., Morgan, D., van Vollenhoven, R., Cifaldi, M., Roy, S., Chen, N., Gotlieb, L., Malaise, M., Langtree, M., Lam, M., Malipeddi, A., Hassan, W., El Miedany, Y., El Gaafary, M., Palmer, D., Dutta, S., Breslin, A., Ahmad, Y., Morcos, P. N., Zhang, X., Grange, S., Schmitt, C., Malipeddi, A. S., Neame, R., Isaacs, J. D., Olech, E., Tak, P. P., Deodhar, A., Keystone, E., Yocum, D., Hessey, E., Read, S., Blunn, K. J., Williams, R. B., McDowell, J. A., Rees, D. H., Young, A., Marks, J. L., Westlake, S. L., Baird, J., Kiely, P. D., Ostor, A. J., Quinn, M. A., Taylor, P. C., Edwards, C. J., Vagadia, V., Bracewell, C., McKay, N., Collini, A., Kidd, E., Wright, D., Watson, K., Williams, E., Mossadegh, S., Ledingham, J., Combe, B., Schwartzman, S., Massarotti, E., Keystone, E. C., Luijtens, K., van der Heijde, D., Mariette, X., Kivitz, A., Stohl, W., Jones, R., Jahreis, A., Armstrong, G., Shaw, T., Westhovens, R., Strand, V., Purcaru, O., Khanna, D.

Volltext

CLINICAL DRUG-DRUG INTERACTIONS (DDIS) THROUGH CYTOCHROME P450 3A (CYP3A) FOR ALECTINIB, A HIGHLY SELECTIVE ALK INHIBITOR von Morcos, PN, Cleary, Y, Dall, G, Guerini, E, Bogman, K, De Petris, L, Ramirez, SV, Bordogna, W, Yu, L, Martin-Facklam, M, Phipps, A

Volltext